Chair
Vanessa Fanning, (AU)
Members
Federico Bozzoli, (IT)
Najia Chafai, (MO)
Vanessa Fanning, (AU)
Bernhard Nordentoft, (DK)
Mike Olex, (US)
Martyn Smith, (UK)
Cory Turner, (CA)
Marie Vaillant, (CA)
Vanessa Fanning, (AU)
Federico Bozzoli, (IT)
Najia Chafai, (MO)
Vanessa Fanning, (AU)
Bernhard Nordentoft, (DK)
Mike Olex, (US)
Martyn Smith, (UK)
Cory Turner, (CA)
Marie Vaillant, (CA)
The People Affected by MS Engagement Coordination Team has an ongoing partnership, with MULTI-ACT, an initiative of the European Union to increase the impact of brain research. As part of their work, the team utilizes the methodology and toolset developed by MULTI-ACT to ensure the active engagement of people affected by MS throughout the research continuum. The partnership with MULTI-ACT has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 787570. Learn more at www.multiact.eu
People affected by MS have been at the heart of the Alliance since its beginning, including individuals serving on the Scientific Steering Committee, the development of the People Affected by MS Engagement Coordination Team and the ongoing partnership with MULTI-ACT.
These principles are available to download.
• Patient problem resolution is at the forefront of all research discussion and decision-making
• Co-design and collaborative decision-making among all stakeholders at all stages, lab-based and clinical
• Clarity of roles among all stakeholders defined
• Communication of all research and clinical trial results
• Processes and results are transparent and accessible
• Patients serve as co-authors in scientific paper development and publication
• Ongoing monitoring and evaluation of the patient engagement process conducted
• The experiential knowledge of patients is valued and acknowledged as part of the research process
• Patients’ perspectives and lived experiences are sought, heard, understood and incorporated in discussions and decision-making
• Expectations provided for all stakeholders so that they can work and communicate meaningfully and effectively
• All stakeholders are empowered to provide their perspective and have them thoughtfully considered
• Trust among stakeholders instills confidence of the honesty, fairness, and reliability of the research process
• Concerted efforts made to include representative populations of patients in clinical research wherever possible including considerations of age, gender, ethnicity, geography, disease state, and socio-economic condition
• Plain language used throughout the research process to ensure active participation by patients
• Experiential knowledge valued as evidence in the research process
• Patient reported outcomes developed, validated and accepted as part of the research and clinical trial process
• No barriers exist to full patient participation
• A plan of support including travel, accommodations, technology and scheduling provided
• Emotional and social support available
• Financial means is not a barrier to participation
• A safe and open environment is provided
• Language should not be a barrier
• Training is provided for all stakeholders